

Appendix 2: Classifications of commoner drugs used to prevent liver rejection

*indicates not specifically licensed in UK for use in liver transplantation

MODE OF ACTION	NAME
Depletion of lymphocytes	Polyclonal antibodies: ALG, thymoglobulin Monoclonal antibodies: OKT3, Alemtuzumab*
Inhibition of lymphocyte activation	Antibodies: IL2R antibodies: Basiliximab, Daclizumab Anti CD80/86 antibodies: Belatacept*
Corticosteroids*	Prednisolone, methylprednisolone
Immunophilin-binding drugs	Calcineurin inhibitors (CNI): Cyclosporin and tacrolimus mTOR Inhibitors: Sirolimus*, Everolimus
Inhibition of de novo nucleotide synthesis	Purine synthesis inhibitors (IMPDH): mycophenolate Pyrimidine synthesis inhibitors (DHODH): Leflunomide*
Anti-metabolites:	Azathioprine, cyclophosphamide*
Inhibitors of lymphocyte trafficking and interaction	Fingolimod* Antibodies to ICAM-1

ALG: anti-lymphocyte globulin; TOR: target of rapamycin; IMPDH: inosine monophosphate dehydrogenase; DHODH: Dihydroorotate dehydrogenase
IL2R: interleukin-2 receptor; ICAM: intercellular adhesion molecule